Government-Owned Inventions; Availability for Licensing, 53489-53490 [2018-23066]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 205 / Tuesday, October 23, 2018 / Notices
Neurological Disorders and Stroke, NIH, 31
Center Drive, Room 8A31, Bethesda, MD
20892, Phone: (301) 451–4460, Email:
Linda.Porter@nih.gov.
Please Note: Any member of the public
interested in submitting written comments to
the Committee must notify the Contact
Person listed on this notice by 5:00 p.m. ET
on Friday, November 2, 2018, with their
request. Interested individuals and
representatives of organizations must submit
a written/electronic copy of the oral
statement/comments including a brief
description of the organization represented
by 5:00 p.m. ET on Friday, November 9,
2018. Statements submitted will be shared
with the committee members and become a
part of the public record.
The meeting will be open to the public and
accessible by live Webcast. Individuals who
participate in person or by using these
electronic services and who need special
assistance, such as captioning or other
reasonable accommodations, should submit a
request to the Contact Person listed on this
notice at least seven days prior to the
meeting.
As a part of security procedures, attendees
should be prepared to present a photo ID
during the security process to get on the NIH
campus. For a full description, please see:
https://www.nih.gov/about/
visitorsecurity.htm.
Information about the IPRCC is available
on the website: https://iprcc.nih.gov/.
Dated: October 16, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–23032 Filed 10–22–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSK30JT082PROD with NOTICES
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; NIA AD/
ADRD Research Collaboratory.
Date: November 20, 2018.
VerDate Sep<11>2014
20:20 Oct 22, 2018
Jkt 247001
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2W200, 7201
Wisconsin Avenue, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Isis S. Mikhail, MD, MPH,
DRPH, National Institute on Aging, Gateway
Building, 7201 Wisconsin Avenue, Suite
2C212, Bethesda, MD 20892, 301–402–7704,
mikhaili@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: October 17, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–23068 Filed 10–22–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; Secondary Data
Analysis (R21) Grant Applications.
Date: November 19, 2018.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge 6700, 6700B Rockledge Drive,
Bethesda, MD 20817 (Telephone Conference
Call).
Contact Person: Brian Hoshaw, Ph.D.,
Scientific Review Officer, National Eye
Institute, National Institutes of Health,
Division of Extramural Research, 5635
Fishers Lane, Suite 1300, Rockville, MD
20892, 301–451–2020, hoshawb@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
53489
Dated: October 17, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–23034 Filed 10–22–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Vince Contreras, 240–669–2823;
vince.contreras@nih.gov. Licensing
information and copies of the U.S.
patent application listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Fusion Glycoprotein Vaccine for
Human Metapneumovirus
Description of Technology: Human
metapneumovirus (hMPV), a negative,
single-stranded RNA virus, accounts for
approximately 5–15% of infant
respiratory tract infections and poses a
severe risk of disease and
hospitalization in both the elderly and
the immunocompromised. Investigators
at the Vaccine Research Center (VRC) of
the National Institute of Allergy and
Infectious Diseases (NIAID) have
generated an hMPV fusion glycoprotein
(‘‘F protein’’) stabilized in a prefusion
conformation.
Stabilizing this prefusion
conformation of the F protein reveals an
immunodominant site which makes it
an ideal vaccine immunogen. The
E:\FR\FM\23OCN1.SGM
23OCN1
53490
Federal Register / Vol. 83, No. 205 / Tuesday, October 23, 2018 / Notices
prefusion stabilized F protein
immunogen can be delivered as either
an isolated homotrimer or trimers
displayed on a nanoparticle. These
immunogens elicit broad and potent
hMPV-neutralizing antibodies.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications:
• Vaccine for prevention of human
metapneumovirus infection
Competitive Advantages:
• No human metapneumovirus vaccine
is currently available
Development Stage:
• In vitro data available
• In vivo animal data available
Inventors: Peter D. Kwong, (NIAID),
Michael Gordon Joyce (NIAID), Peter L.
Collins (NIAID), Ursula J. Buchholz
(NIAID), Guillaume Stewart-Jones
(NIAID), Baoshan Zhang (NIAID),
Yongping Yang (NIAID), Davide Corti
(Institute for Research in Biomedicine),
Antonio Lanzavecchia (Institute for
Research in Biomedicine).
Intellectual Property: HHS Reference
Number E–260–2014 includes U.S.
Provisional Patent Application No. 62/
096,744, filed December 24, 2014; PCT
Application No. PCT/IB2015/059991,
filed December 24, 2015; U.S. Patent
Application No 15/539,640 filed June
23, 2017; EPO Patent Application No.
15831073.0, filed 21 July 2017.
Licensing Contact: Dr. Vince
Contreras, 240–669–2823;
vince.contreras@nih.gov.
Dated: October 10, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2018–23066 Filed 10–22–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSK30JT082PROD with NOTICES
National Institute on Aging; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute on
Aging Special Emphasis Panel, October
17, 2018, 09:00 a.m. to October 17, 2018,
01:00 p.m., Hyatt Regency Bethesda,
One Bethesda Metro Center, 7400
Wisconsin Avenue, Bethesda, MD 20814
which was published in the Federal
Register on September 20, 2018, 83 FR
47634.
The meeting notice is amended to
change the date of the meeting from
VerDate Sep<11>2014
20:20 Oct 22, 2018
Jkt 247001
October 17, 2018 to October 17–18,
2018. The meeting is closed to the
public.
Dated: October 17, 2018.
Melanie J. Pantoja,
Program Analyst,Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–23067 Filed 10–22–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: AIDS and Related
Research Integrated Review Group;
Population and Public Health Approaches to
HIV/AIDS Study Section.
Date: November 8–9, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Suites—Old Town
Alexandria, 801 N Saint Asaph St.,
Alexandria, VA 22314.
Contact Person: Jose H. Guerrier, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5222,
MSC 7852, Bethesda, MD 20892, 301–435–
1137, guerriej@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; AIDS and
Related Research.
Date: November 9, 2018.
Time: 3:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Barna Dey, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3184,
Bethesda, MD 20892, 301–451–2796,
bdey@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Radiation Therapeutics and Biology.
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Date: November 14, 2018.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Nicholas J. Donato, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040,
Bethesda, MD 20892, 301–827–4810,
nick.donato@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Cardiovascular and Surgical Devices.
Date: November 15–16, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crystal Gateway Marriott, 1700
Jefferson Davis Highway, Arlington, VA
22202.
Contact Person: Jan Li, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5106,
Bethesda, MD 20892, 301.402.9607,
Jan.Li@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Instrumentation, Environmental,
and Occupational Safety.
Date: November 15–16, 2018.
Time: 8:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott, 5520
Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Marie-Jose Belanger, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm. 6188 MSC
7804, Bethesda, MD 20892, 301–435–1267,
belangerm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Respiratory Sciences.
Date: November 15–16, 2018.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ghenima Dirami, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4122,
MSC 7814, Bethesda, MD 20892, 240–498–
7546, diramig@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Animal/Biological and Related Resources.
Date: November 15, 2018.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Baishali Maskeri, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2022,
E:\FR\FM\23OCN1.SGM
23OCN1
]]>Agencies
[Federal Register Volume 83, Number 205 (Tuesday, October 23, 2018)]
[Notices]
[Pages 53489-53490]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-23066]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Dr. Vince Contreras, 240-669-2823;
[email protected]. Licensing information and copies of the U.S.
patent application listed below may be obtained by communicating with
the indicated licensing contact at the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required
to receive copies of unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Fusion Glycoprotein Vaccine for Human Metapneumovirus
Description of Technology: Human metapneumovirus (hMPV), a
negative, single-stranded RNA virus, accounts for approximately 5-15%
of infant respiratory tract infections and poses a severe risk of
disease and hospitalization in both the elderly and the
immunocompromised. Investigators at the Vaccine Research Center (VRC)
of the National Institute of Allergy and Infectious Diseases (NIAID)
have generated an hMPV fusion glycoprotein (``F protein'') stabilized
in a prefusion conformation.
Stabilizing this prefusion conformation of the F protein reveals an
immunodominant site which makes it an ideal vaccine immunogen. The
[[Page 53490]]
prefusion stabilized F protein immunogen can be delivered as either an
isolated homotrimer or trimers displayed on a nanoparticle. These
immunogens elicit broad and potent hMPV-neutralizing antibodies.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications:
Vaccine for prevention of human metapneumovirus infection
Competitive Advantages:
No human metapneumovirus vaccine is currently available
Development Stage:
In vitro data available
In vivo animal data available
Inventors: Peter D. Kwong, (NIAID), Michael Gordon Joyce (NIAID),
Peter L. Collins (NIAID), Ursula J. Buchholz (NIAID), Guillaume
Stewart-Jones (NIAID), Baoshan Zhang (NIAID), Yongping Yang (NIAID),
Davide Corti (Institute for Research in Biomedicine), Antonio
Lanzavecchia (Institute for Research in Biomedicine).
Intellectual Property: HHS Reference Number E-260-2014 includes
U.S. Provisional Patent Application No. 62/096,744, filed December 24,
2014; PCT Application No. PCT/IB2015/059991, filed December 24, 2015;
U.S. Patent Application No 15/539,640 filed June 23, 2017; EPO Patent
Application No. 15831073.0, filed 21 July 2017.
Licensing Contact: Dr. Vince Contreras, 240-669-2823;
[email protected].
Dated: October 10, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-23066 Filed 10-22-18; 8:45 am]
BILLING CODE 4140-01-P
